Start here if you're new
what it is
Nutriband develops transdermal drug patches, led by an abuse-deterrent fentanyl patch.
how it gets paid
Last year Nutriband made $2M in revenue. Pocono Pharmaceuticals was the main engine at $1.10M, or 55% of sales.
why it's growing
Trailing-year revenue grew about 2.6% on a tiny base. Single-quarter vs. prior year percentages can look enormous—do not stack those next to the full-year rate without checking the compare period.
what just happened
Nutriband posted $2M in revenue and still lost money.
At a glance
C++ balance sheet — some cracks in the foundation
35/100 earnings predictability — expect surprises
~-$2.54 EPS in cited print (vs. ~-$0.99 FY est. in some feeds—reconcile)
$2M fy2024 rev est
operating result vs sales — margin not meaningful
xvary composite: 34/100 — weak
What they do
Nutriband develops transdermal drug patches, led by an abuse-deterrent fentanyl patch.
You are betting on a niche patch maker with $0M long-term debt. Its lead program, AVERSA Fentanyl, pairs an approved generic patch with abuse-deterrent tech. That is real structure, not vibes. But $2M in annual revenue versus heavy operating losses relative to sales says the moat is thin.
How they make money
$2M
annual revenue · their business grew +2.6% last year
Pocono Pharmaceuticals
$1.10M
AVERSA Fentanyl
$0.50M
Transdermal technology
$0.25M
Other development services
$0.15M
The products that matter
manufactures transdermal patches
Contract Manufacturing
$2M revenue
it's the only revenue stream shown on this page; growth rates bounce on a $2M base, so anchor to the ~2.6% trailing-year figure in the summary rather than one quarter's headline percent.
100% of shown revenue
abuse-deterrent patch candidate
AVERSA Fentanyl
small revenue in table
the segment table shows a small AVERSA line versus contract manufacturing—the equity story is still mostly pipeline upside. if that asset stalls, the current business is too small to carry the story alone.
lead catalyst
drug-delivery intellectual property
Abuse-deterrent transdermal patches
29.2% gross margin
the current gross margin is 29.2%, which means the company keeps about 29 cents of each revenue dollar after direct costs. that is usable math, but on only $2M of sales it is not enough to make the company self-funding.
platform bet
Key numbers
$2M
annual revenue
That is tiny against a $45M market cap. You are paying about 22.5x sales.
n/m
operating margin
With tiny revenue and large operating losses, a positive “% margin” from feeds is meaningless—think dollars lost versus dollars sold, not a ratio headline.
$0M
long-term debt
No debt helps, but it also says lenders are not doing the heavy lifting.
5/100
price stability
A score this low means small news can whip the stock around.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for NTRB right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Nutriband posted $2M in revenue and still lost money.
EPS was about -$2.54 in the underlying print. Gross margin was 29.2%, which helps on direct costs, but it does not cover the operating loss on this scale.
$2M
revenue
-$2.54
eps (print)
29.2%
gross margin
revenue surge
Revenue hit $2M, but that still leaves the company far from self-funding.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the main risk is brutally simple: AVERSA Fentanyl does not become a real commercial asset fast enough. If that happens, you are left valuing a $45M company on a $2M revenue base, a 29.2% gross margin, and projected losses of -$0.99 per share.
med
AVERSA Fentanyl fails clinically, regulatorily, or commercially
This is the center of gravity in the valuation. If the lead patch disappoints at any stage, the story drops back to what exists today: a tiny contract manufacturing business and a lot less narrative support.
Impact: the market would have to lean much harder on the existing $2M revenue stream, which is not enough to justify much optimism by itself.
med
the company needs more capital before the thesis matures
A -$0.99 EPS estimate on just $2M of revenue means internal funding power is thin. $0M of long-term debt helps, but a clean debt line is not the same thing as a comfortable runway.
Impact: if progress takes longer than investors expect, dilution can matter more to your return than any single product headline.
med
the base business stops buying time
Contract manufacturing accounts for 100% of the revenue shown here. If that segment stalls on a $2M base, there is no second proven revenue pillar on this page to absorb the hit.
Impact: the operating floor looks weaker very quickly, especially when gross margin is 29.2% and price stability is only 5 / 100.
Put the pieces together and the risk picture is clear: this stock has a wide range of outcomes because the present business is small, the losses are real, and the future asset still needs proof.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
the next operating update
You want to see whether revenue moves above the current $2M level or just stays stuck while the market waits on something bigger.
trend
whether contract manufacturing keeps growing from here
Quarterly growth rates can look huge on a $2M base; what matters is whether the level of sales keeps compounding. The business has to keep expanding if it is going to matter.
risk
AVERSA Fentanyl milestone quality
Here’s the thing: not every milestone deserves the same reaction. Watch for updates that improve approval odds or commercial odds, not just headlines that fill time.
metric
gross margin versus operating losses
A 29.2% gross margin only matters if it starts supporting the full income statement. If losses stay near -$0.99 per share, the margin number is trivia, not progress.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, nobody has built a clean consensus around the story.
risk profile
volatile
1.8 beta and 5 / 100 price stability translate to a simple message: this can swing hard, and often for reasons that have more to do with milestones than earnings.
chart momentum
catalyst-driven
this chart follows program headlines and financing expectations more than slow, steady fundamentals. that's normal for a name this early.
earnings predictability
35/100
earnings predictability this low means you should expect noise, uneven timing, and model revisions. if you want clean quarterly patterns, this is the wrong ticker.
source: institutional data
Institutional activity
institutional ownership data for NTRB is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive